CATEGORY: IMMUNE HEALTH
One injection of clesrovimab, a laboratory-made antibody against respiratory syncytial virus, cut medically attended RSV lung infections by 60.4% and RSV hospitalizations by 84.2% among 3,614 healthy infants going through their first RSV season.1 The raw counts run like this. Of the 2,398 babies given the antibody, 9 were hospitalized for RSV within five months of the shot, against 28 of the 1,201 given placebo. The placebo group was half the size.
Borrowed Armor Instead of Basic Training
RSV is a common winter virus that most children catch by age two. In the youngest infants it can inflame the smallest airways of the lungs and turn feeding and breathing into hard work. A vaccine is basic training: it teaches the immune system to build its own defenses over several weeks. A monoclonal antibody such as clesrovimab skips the training entirely. The protective antibody is manufactured in a laboratory and handed over ready-made, like borrowed armor that fits the moment it goes on. That immediacy is what suits newborns, whose own immune systems are still too immature for a strong response during the very months when RSV is most dangerous to them.
How 3,614 Babies Were Counted
Healthy infants entering their first RSV season were allocated at random, two to the antibody for every one to placebo, with neither families nor clinicians told which a child had received. Every antibody recipient got a single 105-milligram injection, the same dose whatever the baby weighed. Researchers then followed each child for 150 days. They recorded every medically attended lower respiratory infection, meaning an illness of the lungs or lower airways that led to a doctor visit, an emergency visit or an admission, and confirmed RSV by laboratory test.
Six in Ten Infections, More Than Eight in Ten Hospital Stays
Medically attended RSV lung infections occurred in 60 of 2,398 antibody recipients against 74 of 1,201 on placebo, an estimated incidence of 2.6% versus 6.5%, or 60.4% fewer (95% confidence interval, 44.1 to 71.9).1 Protection ran stronger still against the most serious outcome, with RSV hospitalizations 84.2% less frequent (95% confidence interval, 66.6 to 92.6). Safety problems did not cluster in the antibody group. Serious adverse events came in at 11.5% of antibody recipients and 12.4% of placebo recipients, a near-identical rate.
A Second Antibody Landed on Nearly the Same Number
Clesrovimab is the second RSV antibody for infants, and its results echo the first. A trial of 8,058 infants in France, Germany and the United Kingdom tested nirsevimab, approved earlier and already in wide use, and found RSV hospitalizations down 83.2%: 11 of 4,037 treated infants were hospitalized against 60 of 4,021 given standard care.2 Two antibodies tested independently, arriving at nearly the same figure, is the kind of agreement that gives a finding weight. The FDA approved clesrovimab in June 2025 for infants entering their first RSV season, and its practical wrinkle is the single fixed dose, where nirsevimab’s dose varies with the infant’s weight. The trial enrolled healthy infants, including some born moderately early; a companion study in infants at higher risk of severe RSV is reported separately. Protection was measured through 150 days, roughly one RSV season, so these figures describe a baby’s first winter rather than lasting immunity.
Key Takeaways
- A single clesrovimab injection reduced medically attended RSV lung infections by 60.4% and RSV hospitalizations by 84.2% over five months among 3,614 healthy infants in a randomized trial.
- In raw counts, RSV put 9 of 2,398 treated infants in hospital against 28 of 1,201 on placebo, and serious adverse events were equally common in both groups.
- An earlier trial of a different antibody, nirsevimab, found nearly identical protection: 83.2% fewer RSV hospitalizations among 8,058 infants.
- Because RSV is so common, even an 84.2% reduction does not put hospitalization out of reach. It shifts the odds substantially for the season when a baby is most vulnerable.